Displaying drugs 1976 - 2000 of 2629 in total
Doxofylline
Doxofylline is a methylxanthine derivative with the presence of a dioxolane group in position 7. As a drug used in the treatment of asthma, doxofylline has shown similar efficacy to theophylline but with significantly fewer side effects in animal and human studies. In contrast with other xanthine derivatives, doxofylline does...
Experimental
Onvansertib
Onvansertib is under investigation in clinical trial NCT03303339 (Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML).).
Investigational
Lunasine
Lunasine is under investigation in clinical trial NCT02709330 (ALS Reversals - Lunasin Regimen).
Investigational
Matched Iupac: … (2R)-4,8-dimethoxy-9-methyl-2-(propan-2-yl)-2H,3H-furo[2,3-b]quinolin-9-ium …
Ulimorelin
Ulimorelin is a novel small molecule ghrelin agonist being developed by Tranzyme Pharma as a first-in-class treatment for both POI and diabetic gastroparesis, serious medical conditions in which motility of the GI tract is severely impaired.
Investigational
Matched Iupac: … (2R,5S,8R,11R)-5-cyclopropyl-11-[(4-fluorophenyl)methyl]-2,7,8-trimethyl-3,4,5,6,7,8,9,10,11,12,13,14,15,16 …
2X-121
2X-121 is under investigation in clinical trial NCT03562832 (Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRP).
Investigational
Matched Iupac: … 11-[(2,3-dihydro-1H-isoindol-2-yl)methyl]-2,3,10,12-tetraazatricyclo[7.3.1.0^{5,13}]trideca-1,5,7,9(13 …
Larsucosterol
Investigational
Tulrampator
Tulrampator is under investigation in clinical trial NCT02626572 (Efficacy and Safety of 3 Doses of S47445 Versus Placebo in Patients With Alzheimer's Disease at Mild to Moderate Stages With Depressive Symptoms).
Investigational
Matched Iupac: … 13-cyclopropyl-6-[2-(3-fluorophenyl)ethyl]-11-oxa-4,5,6,13-tetraazatricyclo[8.4.0.0^{3,8}]tetradeca-1 …
Ncs-Chromophore
Experimental
Matched Iupac: … (4S,6R,9E,11R,12R)-11-{[(2R,3R,4R,5R,6R)-4,5-dihydroxy-6-methyl-3-(methylamino)oxan-2-yl]oxy}-4-[(4R) ... -2-oxo-1,3-dioxolan-4-yl]-5-oxatricyclo[8.3.0.0^{4,6}]trideca-1(13),9-dien-2,7-diyn-12-yl 2-hydroxy-7 …
Heptaethylene glycol
Experimental
Lenvervimab
Investigational
UNDECA-3,7-DIENE-1,3,7,11-TETRACARBALDEHYDE
Experimental
Selisistat
Selective inhibitor of SIRT1 that does not inhibit histone deacetylase (HDAC) or other sirtuin deacetylase family members (IC50 values are 98, 19600, 48700, > 100000 and > 100000 nM for SIRT1, SIRT2, SIRT3, HDAC and NADase respectively). Enhances p53 acetylation in response to DNA damaging agents.
Experimental
Homochlorcyclizine
Experimental
3,6,9,12,15,18-HEXAOXAICOSANE
Experimental
Canoctakin
Investigational
XR5944
XR5944 is a DNA bis-intercalating anticancer drug. It has both intercalating and antineoplastic activities.
Investigational
Matched Iupac: … 9-methyl-N-(2-{[2-({2-[(9-methylphenazin-1-yl)formamido]ethyl}amino)ethyl]amino}ethyl)phenazine-1-carboxamide …
LJP 1082
LJP 1082 is a Toleragen that is designed to shut down the B cells that produce antibodies to ß2 GP1. LJP 1082 is undergoing trial for for the treatment of stroke, deep-vein thrombosis and other conditions associated with antibody-mediated thrombosis. Antibody-mediated thrombosis, also called antiphospholipid syndrome (APS), is a blood...
Investigational
Matched Description: … To date, our scientists have shown that approximately 90% of patients studied with antibody-mediated …
Zilovertamab
Investigational
3,6,9,12,15-Pentaoxaheptadecane
Experimental
Displaying drugs 1976 - 2000 of 2629 in total